Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,631 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Oza AM. Kristeleit R, et al. Among authors: thomas d. Lancet Oncol. 2022 Apr;23(4):465-478. doi: 10.1016/S1470-2045(22)00122-X. Epub 2022 Mar 14. Lancet Oncol. 2022. PMID: 35298906 Clinical Trial.
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury S. Grivas P, et al. Among authors: thomas d. BMC Cancer. 2021 May 24;21(1):593. doi: 10.1186/s12885-021-08085-z. BMC Cancer. 2021. PMID: 34030643 Free PMC article. Clinical Trial.
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verweij J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, et al. Bramwell VH, et al. Among authors: thomas d. Cancer Chemother Pharmacol. 1993;31 Suppl 2:S180-4. Cancer Chemother Pharmacol. 1993. PMID: 8453694 Clinical Trial.
Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. The Clinical Screening Group of the European Organization for Research and Treatment of Cancer.
Hurteloup P, Armand JP, Schneider M, Bastit P, Chevallier B, Pourny C, Keiling R, de Oliveira C, Hayat M, Thomas D, et al. Hurteloup P, et al. Among authors: thomas d. Eur J Cancer Clin Oncol. 1989 Mar;25(3):423-8. doi: 10.1016/0277-5379(89)90254-x. Eur J Cancer Clin Oncol. 1989. PMID: 2702996
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
Steward WP, Verweij J, Somers R, Blackledge G, Clavel M, Van Oosterom AT, Greifenberg B, Soedirman J, Thomas D, Van Glabbeke M, et al. Steward WP, et al. Among authors: thomas d. J Cancer Res Clin Oncol. 1991;117 Suppl 4:S193-7. doi: 10.1007/BF01613226. J Cancer Res Clin Oncol. 1991. PMID: 1795008 Clinical Trial.
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group.
Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, van Oosterom AT, Buesa J, Pinedo HM, Thomas D, et al. Mouridsen HT, et al. Among authors: thomas d. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1477-83. doi: 10.1016/0277-5379(87)90089-7. Eur J Cancer Clin Oncol. 1987. PMID: 3479329 Clinical Trial.
10,631 results
You have reached the last available page of results. Please see the User Guide for more information.